Andrew M. Goldsweig, MD, MS, FSCAI, is the incoming Director of the Cardiac Catheterization Laboratory and Director of Cardiovascular Clinical Research at Baystate Medical Center in Springfield, Massachusetts. He previously served as Medical Director of the Structural Heart Disease Program at the University of Nebraska Medical Center. His clinical practice includes LAAO, PFO, TEER, TAVR, PVL, and coronary interventions. His research interests include clinical trials and SHD procedure outcomes and utilization. He has been an investigator in the TAVR UNLOAD, Optimize PRO, CHAMPION-AF, ASAP TOO, TRANSCEND, PARADIGM AVP3, OCCLUFLEX, and MINT trials. He is Chair of the SCAI SHD Council, a member of the SCAI Publications and Government Relations Committees, and an associate editor for JSCAI. He is an editorial board member for Circulation: Cardiovascular Interventions, Catheterization and Cardiovascular Interventions, the American Heart Journal and Cardiovascular Revascularization Medicine. He also serves as an AMA CPT Panel Advisor on behalf of SCAI. He is a member of the NCDR LAAO Registry Steering Committee, the HeartPAC Executive Board, as well as the outgoing governor of the Nebraska ACC Chapter. 

In 2022, Dr. Goldsweig was the recipient of the inaugural SCAI-Medtronic Early Career Research Grant for his project, "Myocardial Infarction in Type 1 vs. Type 2 Diabetes."